Cargando…
The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA)
OBJECTIVES: To elucidate antibody responses after the second and third dose of COVID-19 vaccine in patients with inflammatory rheumatic diseases (IRD) treated with biologic/targeted disease modifying anti-rheumatic drugs (b/ts DMARDs). METHODS: Antibody levels to antigens representing spike full len...
Autores principales: | Frodlund, Martina, Nived, Per, Chatzidionysiou, Aikaterini, Södergren, Anna, Klingberg, Eva, Bengtsson, Anders, Hansson, Monika, Olsson, Sophie, Pin, Elisa, Klareskog, Lars, Kapetanovic, Meliha C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070777/ https://www.ncbi.nlm.nih.gov/pubmed/37076360 http://dx.doi.org/10.1016/j.vaccine.2023.03.065 |
Ejemplares similares
-
High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry
por: Marques, Claudia Diniz Lopes, et al.
Publicado: (2021) -
Correction: High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV brasil registry
Publicado: (2021) -
Reuma.pt/vasculitis – the Portuguese vasculitis registry
por: Ponte, Cristina, et al.
Publicado: (2020) -
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data
por: Marques, Claudia Diniz Lopes, et al.
Publicado: (2022) -
Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt
por: C. Romão, Vasco, et al.
Publicado: (2015)